Literature DB >> 28027587

Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis.

Kasper S Wang1, Greg Tiao2, Lee M Bass3, Paula M Hertel4, Douglas Mogul5, Nanda Kerkar1, Matthew Clifton6, Colleen Azen1, Laura Bull7, Philip Rosenthal7, Dylan Stewart5, Riccardo Superina3, Ronen Arnon8, Molly Bozic9, Mary L Brandt4, Patrick A Dillon10, Annie Fecteau11, Kishore Iyer8, Binita Kamath11, Saul Karpen6, Frederick Karrer12, Kathleen M Loomes13, Cara Mack12, Peter Mattei13, Alexander Miethke2, Kyle Soltys14, Yumirle P Turmelle10, Karen West9, Jessica Zagory1, Cat Goodhue1, Benjamin L Shneider4,14.   

Abstract

To evaluate the efficacy of nontransplant surgery for pediatric cholestasis, 58 clinically diagnosed children, including 20 with Alagille syndrome (ALGS), 16 with familial intrahepatic cholestasis-1 (FIC1), 18 with bile salt export pump (BSEP) disease, and 4 others with low γ-glutamyl transpeptidase disease (levels <100 U/L), were identified across 14 Childhood Liver Disease Research Network (ChiLDReN) centers. Data were collected retrospectively from individuals who collectively had 39 partial external biliary diversions (PEBDs), 11 ileal exclusions (IEs), and seven gallbladder-to-colon (GBC) diversions. Serum total bilirubin decreased after PEBD in FIC1 (8.1 ± 4.0 vs. 2.9 ± 4.1 mg/dL, preoperatively vs. 12-24 months postoperatively, respectively; P = 0.02), but not in ALGS or BSEP. Total serum cholesterol decreased after PEBD in ALGS patients (695 ± 465 vs. 457 ± 319 mg/dL, preoperatively vs. 12-24 months postoperatively, respectively; P = 0.0001). Alanine aminotransferase levels increased in ALGS after PEBD (182 ± 70 vs. 260 ± 73 IU/L, preoperatively vs. 24 months; P = 0.03), but not in FIC1 or BSEP. ALGS, FIC1, and BSEP patients experienced less severely scored pruritus after PEBD (ALGS, 100% vs. 9% severe; FIC1, 64% vs. 10%; BSEP, 50% vs. 20%, preoperatively vs. >24 months postoperatively, respectively; P < 0.001). ALGS patients experienced a trend toward greater freedom from xanthomata after PEBD. There was a trend toward decreased pruritus in FIC1 after IE and GBC. Vitamin K supplementation increased in ALGS after PEBD (33% vs. 77%; P = 0.03). Overall, there were 15 major complications after surgery. Twelve patients (3 ALGS, 3 FIC1, and 6 BSEP) subsequently underwent liver transplantation.
CONCLUSION: This was a multicenter analysis of nontransplant surgical approaches to intrahepatic cholestasis. Approaches vary, are well tolerated, and generally, although not uniformly, result in improvement of pruritus and cholestasis. (Hepatology 2017;65:1645-1654).
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2017        PMID: 28027587      PMCID: PMC5397365          DOI: 10.1002/hep.29019

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  34 in total

1.  An outstanding non-transplant surgical intervention in progressive familial intrahepatic cholestasis: partial internal biliary diversion.

Authors:  F Gün; B Erginel; O Durmaz; S Sökücü; T Salman; A Celik
Journal:  Pediatr Surg Int       Date:  2010-06-20       Impact factor: 1.827

2.  Outcome of partial internal biliary diversion for intractable pruritus in children with cholestatic liver disease.

Authors:  P Ramachandran; N P Shanmugam; S Al Sinani; V Shanmugam; S Srinivas; M Sathiyasekaran; V Tamilvanan; M Rela
Journal:  Pediatr Surg Int       Date:  2014-07-27       Impact factor: 1.827

3.  Progressive familial intrahepatic cholestasis: partial biliary diversion normalizes serum lipids and improves growth in noncirrhotic patients.

Authors:  M Melter; B Rodeck; R Kardorff; P F Hoyer; C Petersen; A Ballauff; J Brodehl
Journal:  Am J Gastroenterol       Date:  2000-12       Impact factor: 10.864

4.  Clinical and biochemical findings in progressive familial intrahepatic cholestasis.

Authors:  P F Whitington; D K Freese; E M Alonso; S J Schwarzenberg; H L Sharp
Journal:  J Pediatr Gastroenterol Nutr       Date:  1994-02       Impact factor: 2.839

5.  Orthotopic liver transplantation for alagille syndrome.

Authors:  G Maldini; E Torri; A Lucianetti; M Guizzetti; D Pinelli; A Bertani; V Corno; M Giovanelli; M Zambelli; P Stroppa; D Alberti; G Torre; M Spada; B Gridelli; M Colledan
Journal:  Transplant Proc       Date:  2005-03       Impact factor: 1.066

6.  Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome.

Authors:  Karan M Emerick; Peter F Whitington
Journal:  Hepatology       Date:  2002-06       Impact factor: 17.425

7.  Preoperative observations and short-term outcome after partial external biliary diversion in 13 patients with progressive familial intrahepatic cholestasis.

Authors:  Henrik Arnell; Sven Bergdahl; Nikos Papadogiannakis; Antal Nemeth; Björn Fischler
Journal:  J Pediatr Surg       Date:  2008-07       Impact factor: 2.545

8.  Progressive familial intrahepatic cholestasis type 1 and extrahepatic features: no catch-up of stature growth, exacerbation of diarrhea, and appearance of liver steatosis after liver transplantation.

Authors:  Panayotis Lykavieris; Saskia van Mil; Danièle Cresteil; Monique Fabre; Michelle Hadchouel; Leo Klomp; Olivier Bernard; Emmanuel Jacquemin
Journal:  J Hepatol       Date:  2003-09       Impact factor: 25.083

9.  Surgical treatment of progressive familial intrahepatic cholestasis: comparison of partial external biliary diversion and ileal bypass.

Authors:  P J Kaliciński; H Ismail; I Jankowska; A Kamiński; J Pawłowska; T Drewniak; M Markiewicz; M Szymczak
Journal:  Eur J Pediatr Surg       Date:  2003-10       Impact factor: 2.191

10.  Bile composition in Alagille Syndrome and PFIC patients having Partial External Biliary Diversion.

Authors:  Karan M Emerick; Marc S Elias; Hector Melin-Aldana; Sandra Strautnieks; Richard J Thompson; Laura N Bull; A s Knisely; Peter F Whitington; Richard M Green
Journal:  BMC Gastroenterol       Date:  2008-10-20       Impact factor: 3.067

View more
  16 in total

1.  Bone Density in Children With Chronic Liver Disease Correlates With Growth and Cholestasis.

Authors:  Kathleen M Loomes; Cathie Spino; Nathan P Goodrich; Thomas N Hangartner; Amanda E Marker; James E Heubi; Binita M Kamath; Benjamin L Shneider; Philip Rosenthal; Paula M Hertel; Saul J Karpen; Jean P Molleston; Karen F Murray; Kathleen B Schwarz; Robert H Squires; Jeffrey Teckman; Yumirle P Turmelle; Estella M Alonso; Averell H Sherker; John C Magee; Ronald J Sokol
Journal:  Hepatology       Date:  2018-12-27       Impact factor: 17.425

Review 2.  Recent developments in diagnostics and treatment of neonatal cholestasis.

Authors:  Amy G Feldman; Ronald J Sokol
Journal:  Semin Pediatr Surg       Date:  2020-07-23       Impact factor: 2.754

3.  Mutation Analysis and Disease Features at Presentation in a Multi-Center Cohort of Children With Monogenic Cholestasis.

Authors:  Paula M Hertel; Laura N Bull; Richard J Thompson; Nathan P Goodrich; Wen Ye; John C Magee; Robert H Squires; Lee M Bass; James E Heubi; Grace E Kim; Sarangarajan Ranganathan; Kathleen B Schwarz; Molly A Bozic; Simon P Horslen; Matthew S Clifton; Yumirle P Turmelle; Frederick J Suchy; Riccardo A Superina; Kasper S Wang; Kathleen M Loomes; Binita M Kamath; Ronald J Sokol; Benjamin L Shneider
Journal:  J Pediatr Gastroenterol Nutr       Date:  2021-08-01       Impact factor: 3.288

4.  Can genetic testing guide the therapy of cholestatic pruritus? A case of benign recurrent intrahepatic cholestasis type 2 with severe nasobiliary drainage-refractory itch.

Authors:  Robert Holz; Andreas E Kremer; Dieter Lütjohann; Hermann E Wasmuth; Frank Lammert; Marcin Krawczyk
Journal:  Hepatol Commun       Date:  2018-01-10

5.  Partial external biliary diversion in bile salt export pump deficiency: Association between outcome and mutation.

Authors:  Philipp Ellinger; Jan Stindt; Carola Dröge; Katharina Sattler; Claudia Stross; Stefanie Kluge; Diran Herebian; Sander H J Smits; Martin Burdelski; Sebastian Schulz-Jürgensen; Antje Ballauff; Jan Schulte Am Esch; Ertan Mayatepek; Dieter Häussinger; Ralf Kubitz; Lutz Schmitt
Journal:  World J Gastroenterol       Date:  2017-08-07       Impact factor: 5.742

6.  Odevixibat and partial external biliary diversion showed equal improvement of cholestasis in a patient with progressive familial intrahepatic cholestasis.

Authors:  Christoph Slavetinsky; Ekkehard Sturm
Journal:  BMJ Case Rep       Date:  2020-06-29

Review 7.  Progressive familial intrahepatic cholestasis: diagnosis, management, and treatment.

Authors:  Mithat Gunaydin; Asudan Tugce Bozkurter Cil
Journal:  Hepat Med       Date:  2018-09-10

8.  Expanding etiology of progressive familial intrahepatic cholestasis.

Authors:  Sarah Af Henkel; Judy H Squires; Mary Ayers; Armando Ganoza; Patrick Mckiernan; James E Squires
Journal:  World J Hepatol       Date:  2019-05-27

9.  Outcomes of surgical management of familial intrahepatic cholestasis 1 and bile salt export protein deficiencies.

Authors:  Laura N Bull; Ludmila Pawlikowska; Sandra Strautnieks; Irena Jankowska; Piotr Czubkowski; Jennifer L Dodge; Karan Emerick; Catherine Wanty; Sami Wali; Samra Blanchard; Florence Lacaille; Jane A Byrne; Albertien M van Eerde; Kaija-Leena Kolho; Roderick Houwen; Steven Lobritto; Vera Hupertz; Patricia McClean; Giorgina Mieli-Vergani; Etienne Sokal; Philip Rosenthal; Peter F Whitington; Joanna Pawlowska; Richard J Thompson
Journal:  Hepatol Commun       Date:  2018-03-30

10.  Placebo-Controlled Randomized Trial of an Intestinal Bile Salt Transport Inhibitor for Pruritus in Alagille Syndrome.

Authors:  Benjamin L Shneider; Cathie Spino; Binita M Kamath; John C Magee; Lee M Bass; Kenneth D Setchell; Alexander Miethke; Jean P Molleston; Cara L Mack; Robert H Squires; Karen F Murray; Kathleen M Loomes; Philip Rosenthal; Saul J Karpen; Daniel H Leung; Stephen L Guthery; Danny Thomas; Averell H Sherker; Ronald J Sokol
Journal:  Hepatol Commun       Date:  2018-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.